Anti-IL6 Receptor Monoclonal Antibody Therapy in NMO. Takashi Yamamura (Japan)

被引：0
|
作者：
Yamamura, Takashi [1 ]
机构：
[1] NCNP, Natl Inst Neurosci, Dept Immunol, Multiple Sclerosis Ctr, Tokyo, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
L-1
引用
收藏
页码：396 / 396
页数：1
相关论文
共 50 条
  • [31] Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab for the treatment of neuromyelitis optica
    Araki, M.
    Matsuoka, T.
    Aranami, T.
    Nakamura, M.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 947 - 947
  • [32] In Vitro characterization of OP-R003-1, a new fully human Anti-IL6 antibody
    Vermot-Desroches, Claudine
    Wang, Wei
    Subiger, Olivier
    Abribat, Thierry
    Alberici, Gilles
    Zauderer, Maurice
    Ernest, Smith
    BLOOD, 2007, 110 (11) : 202B - 202B
  • [33] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [34] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Yoshizaki, K
    Nishimoto, N
    Mihara, M
    Kishimoto, T
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2): : 247 - 259
  • [35] The effect of Neuromyelitis optica (NMO)-IgG and anti-IL-6 receptor monoclonal antibody (SA237; satralizumab) for barrier function at the Blood-Brain Barrier in vitro
    Takeshita, Y.
    Serizawa, K.
    Fujikawa, S.
    Shimizu, F.
    Maeda, T.
    Sano, Y.
    Koga, M.
    Kanda, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 208 - 209
  • [36] Anti-IL6 antibody (ab) based strategies improve the management of HIV negative Castleman's disease
    van Rhee, F
    Alikhan, M
    Munshi, N
    Walker, R
    Waldron, J
    Tricot, G
    Barlogie, B
    BLOOD, 2004, 104 (11) : 897A - 897A
  • [37] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [38] Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Michinori Ogura
    Yu Abe
    Tatsuya Suzuki
    Kensei Tobinai
    Kiyoshi Ando
    Masafumi Taniwaki
    Dai Maruyama
    Minoru Kojima
    Junya Kuroda
    Meguru Achira
    Koho Iizuka
    International Journal of Hematology, 2015, 101 : 286 - 294
  • [39] Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
    Suzuki, Kenshi
    Ogura, Michinori
    Abe, Yu
    Suzuki, Tatsuya
    Tobinai, Kensei
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Maruyama, Dai
    Kojima, Minoru
    Kuroda, Junya
    Achira, Meguru
    Iizuka, Koho
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 286 - 294
  • [40] SPECIFIC IMMUNOSUPPRESSIVE THERAPY BY MONOCLONAL ANTI-IL 2 RECEPTOR ANTIBODY AND ITS SYNERGISTIC ACTION WITH CYCLOSPORINE
    DIAMANTSTEIN, T
    VOLK, HD
    TILNEY, NL
    KUPIECWEGLINSKI, J
    IMMUNOBIOLOGY, 1986, 172 (3-5) : 391 - 399
12345